Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

Jemal, 2006, Cancer statistics 2006, CA Cancer J Clin, 56, 106, 10.3322/canjclin.56.2.106 Lam, 2005, Novel approaches in the therapy of metastatic renal cell carcinoma, World J Urol, 23, 202, 10.1007/s00345-004-0466-0 Mickisch, 2005, Combination of surgery and immunotherapy in metastatic renal cell carcinoma, World J Urol, 23, 191, 10.1007/s00345-004-0468-y Motzer, 1996, Renal-cell carcinoma, N Engl J Med, 335, 865, 10.1056/NEJM199609193351207 National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology: kidney cancer (v.1.2007). http://www.nccn.org/professionals/physician%5Fgls/PDF/kidney.pdf (accessed October 2006). American Cancer Society. Cancer facts and figures; 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf (accessed October 2006). Vogelzang, 1998, Kidney cancer, Lancet, 352, 1691, 10.1016/S0140-6736(98)01041-1 Chow, 1999, Rising incidence of renal cell cancer in the United States, JAMA, 281, 1628, 10.1001/jama.281.17.1628 Hock, 2002, Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data, J Urol, 167, 57, 10.1016/S0022-5347(05)65382-7 Hollingsworth, 2006, Rising incidence of small renal masses: a need to reassess treatment effect, J Natl Cancer Inst, 98, 1331, 10.1093/jnci/djj362 Jayson, 1998, Increased incidence of serendipitously discovered renal cell carcinoma, Urology, 51, 203, 10.1016/S0090-4295(97)00506-2 Lindblad, 2004, Epidemiology of renal cell carcinoma, Scand J Surg, 93, 88, 10.1177/145749690409300202 Murai, 2004, Renal cell carcinoma: etiology, incidence and epidemiology, Curr Opin Urol, 14, 229, 10.1097/01.mou.0000135078.04721.f5 Rathmell, 2004, Renal cell carcinoma, Curr Opin Oncol, 16, 247, 10.1097/00001622-200405000-00010 Rathmell, 2005, Renal cell carcinoma, Curr Opin Oncol, 17, 261, 10.1097/01.cco.0000155007.51495.d6 Rini, 2006, Renal cell carcinoma, Curr Opin Oncol, 18, 289, 10.1097/01.cco.0000219260.60714.c4 Wallen E, Pruthi R. The burden of kidney cancer in America: the urologic diseases in America Project. In: Paper presented at: American Urological Association Annual Meeting 2006; abstract 226; May 20–25; 2006. Yuan, 1998, Hypertension, obesity and their medications in relation to renal cell carcinoma, Br J Cancer, 77, 1508, 10.1038/bjc.1998.248 Hainsworth, 2005, Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib, J Clin Oncol, 23, 7889, 10.1200/JCO.2005.01.8234 Mickisch, 2002, Multimodality treatment of metastatic renal cell carcinoma, Expert Rev Anticancer Ther, 2, 681, 10.1586/14737140.2.6.681 Stadler, 2005, Targeted agents for the treatment of advanced renal cell carcinoma, Cancer, 104, 2323, 10.1002/cncr.21453 Childs, 2000, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation, N Engl J Med, 343, 750, 10.1056/NEJM200009143431101 Linehan, 2004, Focus on kidney cancer, Cancer Cell, 6, 223, 10.1016/j.ccr.2004.09.006 Motzer, 2000, Systemic therapy for renal cell carcinoma, J Urol, 163, 408, 10.1016/S0022-5347(05)67889-5 Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/, (accessed November 2007). Eton, 2006, A brief symptom index for advanced renal cell carcinoma, Health Qual Life Outcomes, 4, 68, 10.1186/1477-7525-4-68 Mickisch, 2001, Guidelines on renal cell cancer, Eur Urol, 40, 252, 10.1159/000049783 Motzer, 2000, Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma, J Clin Oncol, 18, 2972, 10.1200/JCO.2000.18.16.2972 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Bukowski, 1997, Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2, Cancer, 80, 1198, 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H Ramsey, 2006, Treatment for renal cancer: are we beyond the cytokine era?, Nat Clin Pract Urol, 3, 478, 10.1038/ncpuro0581 Yang, 1994, Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report, J Clin Oncol, 12, 1572, 10.1200/JCO.1994.12.8.1572 Yang, 2003, Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer, J Clin Oncol, 21, 3127, 10.1200/JCO.2003.02.122 Avastin package Insert 2006. Genentech, SF, CA. http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp, (accessed February 2007). Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Nexavar(R) Package Insert, 2006. Bayer Healthcare Corporation, Leverkusen, Germany. http://www.univgraph.com/bayer/inserts/nexavar.pdf, (accessed February 2007). Sutent(R) Package Insert 2007. Pfizer inc. New York, NY. http://www.pfizer.com/pfizer/download/uspi_sutent.pdf, (accessed December 2006). Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Vogelzang, 2006, Treatment options in metastatic renal carcinoma: an embarrassment of riches, J Clin Oncol, 24, 1, 10.1200/JCO.2005.03.7234 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Pantuck, 2001, Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma, N Engl J Med, 345, 1711, 10.1056/NEJM200112063452317 International Agency for Research on Cancer (IARC). GLOBOCAN database 2002. http://www-dep.iarc.fr, (accessed July 2006). Zbrozek AS, Gilden DM, Kubisiak J, Lee A. Burden of illness study of lung, pancreatic, and renal cell cancers. In: Paper presented at: ASCO annual meeting proceedings 2002; abstract 2592; 2002. Motzer, 2000, Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J Clin Oncol, 18, 1928, 10.1200/JCO.2000.18.9.1928 Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. http://seer.cancer.gov/csr/1975_2002/, (accessed November 2006). Brown, 2001, The burden of illness of cancer: economic cost and quality of life, Annu Rev Public Health, 22, 91, 10.1146/annurev.publhealth.22.1.91 U.S. Bureau of labor Statistics., Division of Consumer Price Indexes. Consumer Price Indexes (CPI). http://www.bls.gov/cpi/home.htm, (accessed February 2007). Allareddy V, Konety BR. Inpatient costs for bladder, kidney, and prostate cancers in the year 2002. A study using the NIS sample. In: Paper presented at: American Urological Association Annual Meeting, May 20–25; 2006; Atlanta, Georgia. abstract 232. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. Burden of illness analysis of renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 14548; 2006. Tsavaris, 2000, Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma, J Interferon Cytokine Res, 20, 685, 10.1089/10799900050116381 ISPOR. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, New Jersey: International Society for Pharmacoeconomics and Outcomes Research; 2003. Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings Part I 2006; abstract 4604; 2006. 1996 Nadler, 2006, Do oncologists believe new cancer drugs offer good value?, Oncologist, 11, 90, 10.1634/theoncologist.11-2-90 Gardner, 1990, Years of potential life lost (YPLL)–what does it measure?, Epidemiology, 1, 322, 10.1097/00001648-199007000-00012 BC Cancer Agency. BC Cancer Statistics: Potential Years of Life Lost. http://www.bccancer.bc.ca/HPI/CancerStatistics/FF/LifeLost.htm, (accessed November 2006). Burnet, 2005, Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research funds, Br J Cancer, 92, 241, 10.1038/sj.bjc.6602321 National Cancer Institute. SEER Cancer Statistics Review 1975–2000. http://seer.cancer.gov/csr/1975_2000/results_merged/topic_year_lost.pdf, (accessed November 2006). Brown, 2001, The burden of illness of cancer: economic cost and quality of life, Annu Rev Public Health, 22, 91, 10.1146/annurev.publhealth.22.1.91 Litwin, 1997, Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study, J Urol, 157, 1608, 10.1016/S0022-5347(01)64807-9 Parker, 2003, Psychosocial and demographic predictors of quality of life in a large sample of cancer patients, Psycho-Oncology, 12, 183, 10.1002/pon.635 American Society of Clinical Oncology, 1996, Outcomes of cancer treatment for technology assessment and cancer treatment guidelines, J Clin Oncol, 14, 671, 10.1200/JCO.1996.14.2.671 Atzpodien, 2003, Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome, Br J Cancer, 89, 50, 10.1038/sj.bjc.6600996 Heinzer, 1999, Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy, J Clin Oncol, 17, 3612, 10.1200/JCO.1999.17.11.3612 Kroger, 1999, Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy – a pilot study, Anticancer Res, 19, 1553 Beaumont J, Cella D, Li J, et al. Patient-Reported Fatigue in Three Sunitinib Malate (SU11248) Phase II Trials for the Treatment of Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor. In: Paper presented at: First Annual Chicago Supportive Oncology Conference 2005 Scientific Posters, October 6–8; 2005; Hotel InterContinental, Chicago, Illinois. Beaumont JL, Cella D, Li JZ, et al. Efficacy and patient-reported outcomes of sunitinib malate (SU11248) in three phase II trials in advanced renal cell carcinoma, gastrointestinal stromal tumor, and neuroendocrine tumor. In: Paper presented at: International Congress on Anti Cancer Treatment (ICACT); January 2006; Paris. Escudier, 2005, Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC), Eur J Cancer Suppl, 3, 226, 10.1016/S1359-6349(05)81089-4 Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B.A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. In: Paper presented at: J Clin Oncol (Meeting Abstracts) 2006; 24: Abstract 4534; 2006. Pantuck, 2001, The changing natural history of renal cell carcinoma, J Urol, 166, 1611, 10.1016/S0022-5347(05)65640-6 Gilewski, 1989, Cost-effectiveness and reimbursement issues in renal cell carcinoma, Semin Oncol, 16, 20 Anastasiadis, 2003, Quality of life aspects in kidney cancer patients: data from a national registry, Supportive Care in Cancer, 11, 700, 10.1007/s00520-003-0484-2 Bacik J, Fairclough D, Murphy B, et al. Quality of Life (QOL) Analysis for a Randomized Phase III Trial of Interferon Alfa-2a (IFN) versus IFN Plus 13-Cis-Retinoic Acid (CRA) in Patients (Pts) with Advanced Renal Cell Carcinoma (RCC). In: Paper presented at: ASCO Annual meeting Proceeding 2000; abstract 1377; 2000. Cohen, 2001, The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial, Cancer, 91, 1949, 10.1002/1097-0142(20010515)91:10<1949::AID-CNCR1218>3.0.CO;2-A Devine, 2003, The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment, Psychooncology, 12, 453, 10.1002/pon.656 Cohen, 2002, Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine, Urol Oncol, 7, 119, 10.1016/S1078-1439(01)00182-X Cole BF, McDermott D, Parker R, et al. The impact of treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) on quality of life (QOL) in patients with metastatic renal cell carcinoma (mRCC). In: Paper presented at: ASCO Annual Meeting Proceedings 2003; abstract 1555; 2003. Joffe, 1996, A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation, Br J Urol, 77, 638, 10.1046/j.1464-410X.1996.09573.x Kondagunta G, Bacik J, Ishill N, et al. Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 4528; 2006. Lee, 2005, A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma, Cancer, 104, 1894, 10.1002/cncr.21410 Phan G, Morton K, Liewehr D, Steinberg S, Rosenberg S, Yang J. Quality of life in patients with metastatic renal cell cancer receiving different regimens of interleukin-2. In: Paper presented at: ASCO Annual Meeting Proceedings 2002; abstract 95; 2002. Plasse T, Goss T, Dutcher J, et al. Quality of life assessment of renal cancer patients treated with interleukin-2, interferon-[alpha] and 5-fluorouracil. In: Paper presented at: ASCO Annual Meeting Proceedings 1998; abstract 260; 1998. Shamash, 2003, IPM chemotherapy in cytokine refractory renal cell cancer, Br J Cancer, 88, 1516, 10.1038/sj.bjc.6600934 Wong, 2002, Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma, Int Med J, 32, 158, 10.1046/j.1444-0903.2001.00184.x